Roche reports promising results from anti-COVID cocktail

Credit: CC0 Public Domain

Swiss pharma giant Roche announced Tuesday promising results from clinical trials of an anti-COVID cocktail developed with US biotech firm Regeneron.

The results of the Phase 3 trial showed that the combination of the casirivimab and imdevimab “reduced hospitalisation or death by 70 percent in non-hospitalised patients with COVID-19,” it said in a statement.

The cocktail also “significantly shortened the duration of symptoms by four days,” from 14 to 10.

Roche said the tests were carried out on people believed to be at higher risk of contracting a severe COVID-19 infection, typically the elderly and those with underlying serious health conditions.

Several have been developing antibody treatments which prevent the virus from replicating in the body, in the hope of finding an to go alongside vaccines to combat emerging variants.

Roche noted that the treatment is the only monoclonal antibody combination which remains effective when confronted with the major variants, some of which are more infectious and cause more serious illness.

Levi Garraway, Roche’s chief medical officer and head of global product development, said “new infections continue to rise globally with over three million reported cases last week.

“This investigational antibody cocktail may offer hope as a potential new therapy to high-risk patients—particularly in light of recent evidence showing that casirivimab and imdevimab together retain activity against key emerging variants,” Garraway said in a statement.

The results will now be passed on to regulators and submitted for peer review.

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2021 AFP

Roche reports promising results from anti-COVID cocktail (2021, March 23)
retrieved 23 March 2021

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Leave a Reply

Your email address will not be published. Required fields are marked *